Trial Profile

An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

Most Recent Events

02 Apr 2019 Status changed from recruiting to completed.
28 Mar 2018 Status changed from not yet recruiting to recruiting.
14 Jun 2017 Planned primary completion date changed from 1 Nov 2019 to 15 Nov 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com